EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Extended ICI treatment after first‐line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non‐small lung cancer: Post hoc analysis from NEJ051 ( REACTIVE study)

Ou Yamaguchi iD, Keita Mori, Saori Takata, Kazuhiko Shibata, Kenichi Chikamori, Nozomu Kimura, Yoshiaki Nagai, Taku Nakagawa, Satoshi Igawa iD, Taishi Harada, Hiroshige Yoshioka, Hisashi Tanaka iD und 6 weitere

Thoracic Cancer · 2024

DOI: 10.1111/1759-7714.15173 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, 2024. Verfasst von Ou Yamaguchi und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Comprehensive Cancer Center, Saitama Medical University International Medical Center, Hidaka, Japan. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eli Lilly Japan K.K..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The factors that predict the clinical response to ramucirumab plus docetaxel (RD) after first‐line chemoimmunotherapy are unresolved. We explored whether the therapeutic efficacy of prior chemoimmunotherapy could predict the outcome of RD as sequential therapy in patients with advanced non‐small cell lung cancer (NSCLC).

Methods

Our study comprised 288 patients with advanced NSCLC who received RD as the second‐line treatment after first‐line chemoimmunotherapy at 62 Japanese institutions. Chemoimmunotherapy consisted of a platinum‐based regimen and immune checkpoint inhibitors (ICIs). The association between several variables and the therapeutic outcome of RD was determined via logistic regression analysis.

Results

Of the 288 patients, 225 (78.1%) received maintenance therapy and 108 (37.5%) received both ICI treatment for >180 days and maintenance therapy. All of 108 patients having ICIs for >180 days received maintenance therapy. Univariate analysis identified performance status, histology (adenocarcinoma), maintenance therapy, and ICI treatment >180 days as significant predictors of better progression‐free survival (PFS) and overall survival (OS) after RD administration. Multivariate analysis confirmed that these factors independently predicted favorable PFS and OS. The therapeutic response and PD‐L1 expression were not closely associated with outcome after RD treatment. In particular, maintenance therapy >4 cycles was more predictive of the better prognosis for RD treatment.

Conclusion

Extended ICI treatment after chemoimmunotherapy and maintenance therapy enhanced the efficacy of second‐line RD treatment in patients with advanced NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungHumansRamucirumabDocetaxelAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

ICIchemoimmunotherapylung cancermaintenance therapypredictiveramucirumab plus docetaxel

Substanzen

RamucirumabDocetaxelAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Comprehensive Cancer Center, Saitama Medical University International Medical Center, Hidaka, Japan.
  • Clinical Research Center, Shizuoka Cancer Center, Nagaizumi, Japan.
  • Department of Respiratory Medicine, Kyorin University Hospital, Mitaka, Japan.
  • Division of Medical Oncology, Department of Medicine, Kouseiren Takaoka Hospital, Takaoka, Japan.
  • Department of Medical Oncology, NHO Yamaguchi-Ube Medical Center, Ube, Japan.
  • Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

ORCID-Profile: Ou Yamaguchi, Satoshi Igawa, Hisashi Tanaka, Hiroaki Satoh, Kyoichi Kaira

Förderung

  • Eli Lilly Japan K.K.

Zitieren

APA

Yamaguchi, O., Mori, K., Takata, S., Shibata, K., Chikamori, K., Kimura, N., Nagai, Y., Nakagawa, T., Igawa, S., Harada, T., Yoshioka, H., Tanaka, H., Nogawa, H., Satoh, H., Shiozawa, T., Tsuji, K., Kobayashi, K., & Kaira, K. (2024). Extended ICI treatment after first‐line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non‐small lung cancer: Post hoc analysis from NEJ051 ( REACTIVE study). Thoracic Cancer. https://doi.org/10.1111/1759-7714.15173

Vancouver

Yamaguchi O, Mori K, Takata S, Shibata K, Chikamori K, Kimura N, et al. Extended ICI treatment after first‐line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non‐small lung cancer: Post hoc analysis from NEJ051 ( REACTIVE study). Thoracic Cancer. 2024. doi:10.1111/1759-7714.15173

BibTeX
@article{Yamaguchi2024,
  author = {Yamaguchi, Ou and Mori, Keita and Takata, Saori and Shibata, Kazuhiko and Chikamori, Kenichi and Kimura, Nozomu and Nagai, Yoshiaki and Nakagawa, Taku and Igawa, Satoshi and Harada, Taishi and Yoshioka, Hiroshige and Tanaka, Hisashi and Nogawa, Hitomi and Satoh, Hiroaki and Shiozawa, Toshihiro and Tsuji, Kosuke and Kobayashi, Kunihiko and Kaira, Kyoichi},
  title = {Extended ICI treatment after first‐line chemoimmunotherapy could predict the clinical benefit of ramucirumab plus docetaxel in advanced non‐small lung cancer: Post hoc analysis from NEJ051 ( REACTIVE study)},
  journal = {Thoracic Cancer},
  year = {2024},
  doi = {10.1111/1759-7714.15173}
}
Kostenlos starten →